Kyowa Kirin’s FKB327 (biosimilar, adalimumab) Receives the MMA Approval in Japan

AstraZeneca Signs Development and Commercialization Agreement with Kyowa Hakko Kirin for its Fasenra (beralizumab)


  • FKB327 (biosimilar, adalimumab) is an injectable medication that involves inhibition of Tumor Necrosis Factor (TNF) blocks the inhibition of activity, thereby reducing inflammation and other disease symptoms including RA, plaque psoriasis, Crohn’s disease, and ulcerative colitis
  • In 2018, Fujifilm signed an agreement with Mylan to commercialize biosimilar adalimumab in EU and will expand it globally in 2019
  • The Kyowa’s FKB327 is the first approved in Japan where Mylan is responsible for its commercialization and has marketed it in 20 countries across EU

Click here to read full press release/ article | Ref: Fujifilm | Image: LinkedIn